Compare GNLN & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLN | CMND |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.4M |
| IPO Year | 2019 | 2021 |
| Metric | GNLN | CMND |
|---|---|---|
| Price | $0.30 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 284.6K | 121.0K |
| Earning Date | 05-14-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | N/A |
| Revenue This Year | $1,541.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.01 | $0.07 |
| 52 Week High | $7.73 | $3.25 |
| Indicator | GNLN | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 26.61 | 54.98 |
| Support Level | N/A | $0.99 |
| Resistance Level | $0.89 | $1.08 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 6.58 | 96.91 |
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.